866-997-4948(US-Canada Toll Free)

Wounds - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 224 Pages

Wounds - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds Pipeline Review, H2 2016, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1, 56, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 7 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Wounds Overview 10
Therapeutics Development 11
Pipeline Products for Wounds - Overview 11
Pipeline Products for Wounds - Comparative Analysis 12
Wounds - Therapeutics under Development by Companies 13
Wounds - Therapeutics under Investigation by Universities/Institutes 17
Wounds - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Wounds - Products under Development by Companies 23
Wounds - Products under Investigation by Universities/Institutes 28
Wounds - Companies Involved in Therapeutics Development 30
Aerpio Therapeutics Inc 30
AlgiPharma AS 31
AmpliPhi Biosciences Corp 32
AndroScience Corp 33
Aridis Pharmaceuticals LLC 34
Beech Tree Labs Inc 35
Bio3 Research Srl 36
Biotec Pharmacon ASA 37
Blueberry Therapeutics Ltd 38
Cellphire Inc 39
CorMedix Inc 40
Dermala Inc 41
Destiny Pharma Ltd 42
Escape Therapeutics Inc 43
EyeGene Inc 44
FibroGen Inc 45
GangaGen Inc 46
Gene Signal International SA 47
GlaxoSmithKline Plc 48
IC-MedTech Inc 49
Living Cell Technologies Ltd 50
Madam Therapeutics BV 51
miRagen Therapeutics Inc 52
NatureWise Biotech & Medicals Corp 53
Novan Inc 54
NuvOx Pharma LLC 55
Octapharma AG 56
Omeros Corp 57
Osiris Therapeutics Inc 58
Pacific Northwest Biotechnology LLC 59
Pharmaxis Ltd 60
ProMetic Life Sciences Inc 61
RiverTown Therapeutics Inc 62
RMB-Research GmbH 63
RXi Pharmaceuticals Corp 64
Sinclair Pharma Plc 65
SomaGenics Inc 66
Stratatech Corp 67
TGV-Laboratories 68
Thesan Pharmaceuticals Inc 69
Topadur Pharma AG 70
Trophogen Inc 71
Tumorend LLC 72
VBS Pharmaceuticals 73
viDA Therapeutics Inc 74
Wounds - Therapeutics Assessment 75
Assessment by Monotherapy Products 75
Assessment by Combination Products 76
Assessment by Target 77
Assessment by Mechanism of Action 80
Assessment by Route of Administration 83
Assessment by Molecule Type 85
Drug Profiles 87
(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 87
A-3APO - Drug Profile 88
ABSA-01 - Drug Profile 89
AKB-4924 - Drug Profile 92
ALLO-ASC - Drug Profile 93
AlloGraf - Drug Profile 94
Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile 95
APO-1 - Drug Profile 96
APO-2 - Drug Profile 97
AR-101 - Drug Profile 98
Arginine Butyrate - Drug Profile 99
ARN-077 - Drug Profile 100
ASCJ-9 - Drug Profile 101
B-244 - Drug Profile 103
BB-1000 - Drug Profile 104
BDM-I - Drug Profile 105
BTL-slo - Drug Profile 107
CAR Peptide - Drug Profile 108
Cell Therapy for Chronic Wounds - Drug Profile 109
Cell Therapy for Dermatology and Immunology - Drug Profile 110
Cell Therapy for Wounds - Drug Profile 112
CM-101 - Drug Profile 113
CRMD-004 - Drug Profile 114
CTR-2 - Drug Profile 115
daprodustat - Drug Profile 116
DB-2121 - Drug Profile 119
Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile 120
Drugs to Agonize Hepatocyte Growth Factor Receptor for Wounds - Drug Profile 121
Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 122
EGS-001 - Drug Profile 123
FG-6874 - Drug Profile 124
G-3KL - Drug Profile 125
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 126
Gene Therapy to Activate HSP60 for Wounds - Drug Profile 127
GS-156 - Drug Profile 128
Human Growth Factor - Drug Profile 129
hVGF - Drug Profile 130
JM-2 - Drug Profile 131
KL-7016 - Drug Profile 132
LWnt-3a - Drug Profile 133
MG-53 - Drug Profile 134
MMP-26051 - Drug Profile 136
MMP-26052 - Drug Profile 137
molgramostim - Drug Profile 138
Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile 139
MRG-110 - Drug Profile 140
Mul-1867 - Drug Profile 141
NBM-67 - Drug Profile 142
ND-336 - Drug Profile 143
NTCELL - Drug Profile 144
Oligomer G for Wounds And Burns - Drug Profile 148
OTI-1011 - Drug Profile 149
OTI-1502 - Drug Profile 150
P-128 - Drug Profile 151
P-148 - Drug Profile 152
Panaecin - Drug Profile 153
perflenapent for wound healing - Drug Profile 154
Perlecan - Drug Profile 155
PGF - Drug Profile 157
plasminogen (recombinant) - Drug Profile 158
Polysaccharide for Wounds and Scars - Drug Profile 159
Protein for Diabetic Wound Healing - Drug Profile 160
Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile 161
Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile 162
Protein to Activate FGF2 for Wound Healing - Drug Profile 163
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 164
PXS-4820 - Drug Profile 165
Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 166
Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile 167
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile 168
Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing - Drug Profile 169
Recombinant Protein to Inhibit SEB and TSST-1 for Pulmonary Infections, Bacterial Infections, Toxic Shock and Wounds - Drug Profile 170
Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 171
RT-1740 - Drug Profile 172
SG-404 - Drug Profile 173
silver sulfadiazine - Drug Profile 174
Small Molecule for MRSA Skin Infection and Wound Healing - Drug Profile 175
Small Molecule to Activate MRTF-A for Wound Healing - Drug Profile 176
Small Molecule to Target LGR6 for Dermatology - Drug Profile 177
Small Molecules for Staphylococcal Infections and Wounds - Drug Profile 178
Small Molecules to Activate iRhom2 for Wound Healing and Oncology - Drug Profile 179
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 180
Soluble Beta Glucan - Drug Profile 181
Statmicoll - Drug Profile 184
Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile 185
Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile 186
Synthetic Peptides for Wound Healing and Neurodegenerative Diseases - Drug Profile 187
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 188
Thrombosomes - Drug Profile 190
Tolecine - Drug Profile 191
TOPN-53 - Drug Profile 192
TRBN-0224 - Drug Profile 193
TWB-103 - Drug Profile 195
V-2248 - Drug Profile 196
VTI-3000 Series - Drug Profile 197
WH-1 - Drug Profile 198
XF-70 - Drug Profile 199
Wounds - Dormant Projects 200
Wounds - Discontinued Products 209
Wounds - Product Development Milestones 210
Featured News & Press Releases 210
Appendix 216
Methodology 216
Coverage 216
Secondary Research 216
Primary Research 216
Expert Panel Validation 216
Contact Us 216
Disclaimer 217

List of Tables
Number of Products under Development for Wounds, H2 2016 18
Number of Products under Development for Wounds - Comparative Analysis, H2 2016 19
Number of Products under Development by Companies, H2 2016 20
Number of Products under Development by Companies, H2 2016 (Contd..1) 21
Number of Products under Development by Companies, H2 2016 (Contd..2) 22
Number of Products under Development by Companies, H2 2016 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2016 25
Comparative Analysis by Late Stage Development, H2 2016 26
Comparative Analysis by Clinical Stage Development, H2 2016 27
Comparative Analysis by Early Stage Development, H2 2016 28
Comparative Analysis by Unknown Stage Development, H2 2016 29
Products under Development by Companies, H2 2016 30
Products under Development by Companies, H2 2016 (Contd..1) 31
Products under Development by Companies, H2 2016 (Contd..2) 32
Products under Development by Companies, H2 2016 (Contd..3) 33
Products under Development by Companies, H2 2016 (Contd..4) 34
Products under Investigation by Universities/Institutes, H2 2016 35
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 36
Wounds - Pipeline by Aerpio Therapeutics Inc, H2 2016 37
Wounds - Pipeline by AlgiPharma AS, H2 2016 38
Wounds - Pipeline by AmpliPhi Biosciences Corp, H2 2016 39
Wounds - Pipeline by AndroScience Corp, H2 2016 40
Wounds - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 41
Wounds - Pipeline by Beech Tree Labs Inc, H2 2016 42
Wounds - Pipeline by Bio3 Research Srl, H2 2016 43
Wounds - Pipeline by Biotec Pharmacon ASA, H2 2016 44
Wounds - Pipeline by Blueberry Therapeutics Ltd, H2 2016 45
Wounds - Pipeline by Cellphire Inc, H2 2016 46
Wounds - Pipeline by CorMedix Inc, H2 2016 47
Wounds - Pipeline by Dermala Inc, H2 2016 48
Wounds - Pipeline by Destiny Pharma Ltd, H2 2016 49
Wounds - Pipeline by Escape Therapeutics Inc, H2 2016 50
Wounds - Pipeline by EyeGene Inc, H2 2016 51
Wounds - Pipeline by FibroGen Inc, H2 2016 52
Wounds - Pipeline by GangaGen Inc, H2 2016 53
Wounds - Pipeline by Gene Signal International SA, H2 2016 54
Wounds - Pipeline by GlaxoSmithKline Plc, H2 2016 55
Wounds - Pipeline by IC-MedTech Inc, H2 2016 56
Wounds - Pipeline by Living Cell Technologies Ltd, H2 2016 57
Wounds - Pipeline by Madam Therapeutics BV, H2 2016 58
Wounds - Pipeline by miRagen Therapeutics Inc, H2 2016 59
Wounds - Pipeline by NatureWise Biotech & Medicals Corp, H2 2016 60
Wounds - Pipeline by Novan Inc, H2 2016 61
Wounds - Pipeline by NuvOx Pharma LLC, H2 2016 62
Wounds - Pipeline by Octapharma AG, H2 2016 63
Wounds - Pipeline by Omeros Corp, H2 2016 64
Wounds - Pipeline by Osiris Therapeutics Inc, H2 2016 65
Wounds - Pipeline by Pacific Northwest Biotechnology LLC, H2 2016 66
Wounds - Pipeline by Pharmaxis Ltd, H2 2016 67
Wounds - Pipeline by ProMetic Life Sciences Inc, H2 2016 68
Wounds - Pipeline by RiverTown Therapeutics Inc, H2 2016 69
Wounds - Pipeline by RMB-Research GmbH, H2 2016 70
Wounds - Pipeline by RXi Pharmaceuticals Corp, H2 2016 71
Wounds - Pipeline by Sinclair Pharma Plc, H2 2016 72
Wounds - Pipeline by SomaGenics Inc, H2 2016 73
Wounds - Pipeline by Stratatech Corp, H2 2016 74
Wounds - Pipeline by TGV-Laboratories, H2 2016 75
Wounds - Pipeline by Thesan Pharmaceuticals Inc, H2 2016 76
Wounds - Pipeline by Topadur Pharma AG, H2 2016 77
Wounds - Pipeline by Trophogen Inc, H2 2016 78
Wounds - Pipeline by Tumorend LLC, H2 2016 79
Wounds - Pipeline by VBS Pharmaceuticals, H2 2016 80
Wounds - Pipeline by viDA Therapeutics Inc, H2 2016 81
Assessment by Monotherapy Products, H2 2016 82
Assessment by Combination Products, H2 2016 83
Number of Products by Stage and Target, H2 2016 85
Number of Products by Stage and Mechanism of Action, H2 2016 88
Number of Products by Stage and Route of Administration, H2 2016 91
Number of Products by Stage and Molecule Type, H2 2016 93
Wounds - Dormant Projects, H2 2016 207
Wounds - Dormant Projects (Contd..1), H2 2016 208
Wounds - Dormant Projects (Contd..2), H2 2016 209
Wounds - Dormant Projects (Contd..3), H2 2016 210
Wounds - Dormant Projects (Contd..4), H2 2016 211
Wounds - Dormant Projects (Contd..5), H2 2016 212
Wounds - Dormant Projects (Contd..6), H2 2016 213
Wounds - Dormant Projects (Contd..7), H2 2016 214
Wounds - Dormant Projects (Contd..8), H2 2016 215
Wounds - Discontinued Products, H2 2016 216

List of Figures
Number of Products under Development for Wounds, H2 2016 18
Number of Products under Development for Wounds - Comparative Analysis, H2 2016 19
Number of Products under Development by Companies, H2 2016 20
Number of Products under Investigation by Universities/Institutes, H2 2016 24
Comparative Analysis by Clinical Stage Development, H2 2016 27
Comparative Analysis by Early Stage Products, H2 2016 28
Assessment by Monotherapy Products, H2 2016 82
Number of Products by Top 10 Targets, H2 2016 84
Number of Products by Stage and Top 10 Targets, H2 2016 84
Number of Products by Top 10 Mechanism of Actions, H2 2016 87
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 87
Number of Products by Top 10 Routes of Administration, H2 2016 90
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 90
Number of Products by Top 10 Molecule Types, H2 2016 92
Number of Products by Stage and Top 10 Molecule Types, H2 2016 92

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *